<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sulfur hexafluoride lipid microspheres: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sulfur hexafluoride lipid microspheres: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sulfur hexafluoride lipid microspheres: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="97563" href="/d/html/97563.html" rel="external">see "Sulfur hexafluoride lipid microspheres: Drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F26147211"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious cardiopulmonary reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes administration. Always have resuscitation equipment and trained personnel readily available.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26419190"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lumason</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F48852392"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Diagnostic Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53945075"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Route of administration varies with indication; use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c6b04ced-0d6c-4156-af66-7863736fbdb3">Hepatic ultrasonography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic ultrasonography:</b> Neonates: IV: 0.03 mL/kg during ultrasonography; may give 1 additional dose of 0.03 mL/kg during procedure if needed. Maximum dose: 2.4 mL/dose. <b>Note:</b> Adjust to low mechanical index (≤0.4) after identification of the target focal lesion on noncontrast ultrasound examination. Continue imaging following injection.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32f23f5b-8f20-4943-befc-cedfd3e5ca10">Urinary ultrasonography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary ultrasonography:</b> Neonates: Intravesical: Instill 1 mL into the bladder via an appropriate size urinary catheter during ultrasonography; bladder may be refilled with NS for a second cycle of voiding and imaging, without the need of a second dose of contrast agent.<b> Note: </b>Adjust to low mechanical index (≤0.4) after baseline noncontrast ultrasound examination. Perform continuous alternate ultrasound imaging of the bladder, ureters, and kidneys during filling and voiding of the bladder.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F46562159"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Route of administration varies with indication; use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3559ea7b-2cf7-45f8-9492-a5e17c36cc76">Echocardiography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Echocardiography:</b> Infants, Children, and Adolescents: IV: 0.03 mL/kg during echocardiography; may give 1 additional dose of 0.03 mL/kg during procedure if needed. Maximum dose: 2 mL/dose.<b> Note:</b> Adjust the mechanical index for the ultrasound device to ≤0.8 after baseline noncontrast echocardiography is complete. Continue imaging following injection.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c6b04ced-0d6c-4156-af66-7863736fbdb3">Hepatic ultrasonography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic</b>
<b> ultrasonography:</b> Infants, Children, and Adolescents: IV: 0.03 mL/kg during ultrasonography; may give 1 additional dose of 0.03 mL/kg during procedure if needed. Maximum dose: 2.4 mL/dose.<b> Note:</b> Adjust to low mechanical index (≤0.4) after identification of the target focal lesion on noncontrast ultrasound examination. Continue imaging following injection.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32f23f5b-8f20-4943-befc-cedfd3e5ca10">Urinary ultrasonography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary ultrasonography:</b> Infants, Children, and Adolescents: Intravesical: Instill 1 mL into the bladder via a 6 to 8 French urinary catheter during ultrasonography; bladder may be refilled with NS for a second cycle of voiding and imaging, without the need of a second dose of contrast agent. <b>Note: </b>Adjust to low mechanical index (≤0.4) after baseline noncontrast ultrasound examination. Perform continuous alternate ultrasound imaging of the bladder, ureters, and kidneys during filling and voiding of the bladder.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51160250"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51160251"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F26418825"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="97563" href="/d/html/97563.html" rel="external">see "Sulfur hexafluoride lipid microspheres: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e87917f7-25b1-473a-abaa-b3eccb619cb2">Cardiovascular imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiovascular imaging: IV:</b> 2 mL during echocardiography; may repeat once during procedure to prolong contrast enhancement.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Adjust the mechanical index for the ultrasound device to 0.8 or lower after baseline non-contrast echocardiography is complete. Continue imaging following injection.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c6b04ced-0d6c-4156-af66-7863736fbdb3">Hepatic ultrasonography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic ultrasonography:</b>
<b>IV:</b> 2.4 mL during ultrasonography; may repeat once during procedure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Adjust to low mechanical index (≤0.4) after identification of the target focal lesion on non-contrast ultrasound examination. Continue imaging following injection.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f97f2d97-422c-432f-8b25-308003446676">Diagnostic vessel assessment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic vessel assessment:</b> SonoVue [Canadian product]: <b>IV:</b> 1.2 mL during Doppler ultrasound; may repeat once during procedure.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990276"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987500"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F26641828"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Nervous system: Headache (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, chest pain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site, warm sensation at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, feeling hot</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, bradycardia, cardiac arrhythmia, hypertension, hypotension, shock, supraventricular tachycardia, syncope, tachycardia, ventricular fibrillation, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Loss of consciousness, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, dyspnea, hypoxia, stridor, wheezing</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (including peripheral edema), flushing, hypertensive crisis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Palatal edema</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema, hypersensitivity reaction (including severe hypersensitivity reaction), mouth edema, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Facial hypoesthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, pharyngeal edema</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Swelling (facial swelling, swelling of eye, swelling of lips, swollen tongue, upper airway swelling)</p></div>
<div class="block coi drugH1Div" id="F26147296"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to sulfur hexafluoride lipid-type A microspheres or any component of the formulation, including polyethylene glycol.</p>
<p style="text-indent:-2em;margin-left:2em;">SonoVue [Canadian product]: Hypersensitivity to sulfur hexafluoride or any component of the formulation; known right-to-left cardiac shunts; severe pulmonary hypertension (pulmonary artery pressure &gt;90 mm Hg); uncontrolled systemic hypertension; adult respiratory distress syndrome.</p></div>
<div class="block war drugH1Div" id="F26416885"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse events:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiopulmonary reactions: <b>[US Boxed Warning]:</b>
<b>Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or shortly following administration of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes administration. Always have resuscitation equipment and trained personnel readily available.</b> Risk is increased in patients with unstable cardiopulmonary conditions (acute MI, acute coronary artery syndromes, worsening or unstable CHF, serious ventricular arrhythmias). Monitor all patients for acute reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Postmarketing reports of serious anaphylactoid reactions (eg, death, shock, bronchospasm, dyspnea, throat tightness, angioedema, edema [oropharyngeal, palatal, peripheral, and localized], swelling [face, eye, lip, tongue, upper airway], facial hypoesthesia, rash, urticaria, pruritus, flushing, erythema) have been reported in patients with no prior exposure. Assess patients for prior hypersensitivity reactions to products containing polyethylene glycol (eg, certain colonoscopy bowel preparations, laxatives); increased risk of serious reactions may occur. Monitor for signs and symptoms of hypersensitivity reactions. Equipment for resuscitation and trained personnel should be readily available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: For IV or intravesical use only; do not administer intra-arterially.</p>
<p style="text-indent:-2em;margin-left:4em;">• High mechanical index values: Not recommended for use at mechanical indices &gt;0.8. High mechanical index values may cause microsphere cavitation or rupture and lead to ventricular arrhythmias; end-systolic triggering with high mechanical indices has also been reported to cause ventricular arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic embolization: After administration to patients with cardiac shunts, some IV injected sulfur hexafluoride lipid-type A microspheres may bypass filtering by the lung and enter the arterial circulation. Assess patients with shunts for embolic phenomena following administration.</p></div>
<div class="block foc drugH1Div" id="F46100862"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lumason: Lipid-type A 25 mg and sulfur hexafluoride 60.7 mg (1 ea) [contains polyethylene glycol (macrogol)]</p></div>
<div class="block geq drugH1Div" id="F46100861"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46251918"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Lumason Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60.7-25 mg (per each): $170.52</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614572"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer as an IV bolus; do not administer intra-arterially. Follow each injection with an intravenous flush of 5 mL NS.</p>
<p style="text-indent:-2em;margin-left:2em;">Intravesical: Empty the bladder of urine, and then fill bladder with NS to ~33% to 50% of predicted total volume. Administer sulfur hexafluoride lipid microspheres as an intravesical bolus injection through an appropriate size urinary catheter (typically 6 to 8 French). Continue filling bladder with NS until patient has the urge to micturate or at first sign of back pressure. Immediately following the first voiding, the bladder may be refilled with NS only for a second cycle of voiding and imaging.</p></div>
<div class="block adm drugH1Div" id="F26418830"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer as an IV bolus; do not administer intra-arterially. Follow each injection with an intravenous flush of NS (5 mL in adults).</p>
<p style="text-indent:-2em;margin-left:4em;">SonoVue [Canadian product]: Administer as an IV bolus; do not administer intra-arterially. The recommended rate of injection during Doppler ultrasound is 1.2 mL over a period of 1 second; however, a slower rate of injection over 2 to 3 seconds is recommended during transcranial Doppler to reduce blooming artifacts. Follow each injection with an intravenous flush of 5 mL NS.</p>
<p style="text-indent:-2em;margin-left:2em;">Intravesical: Empty the bladder of urine, and then fill bladder with NS to ~33% to 50% of predicted total volume. Administer sulfur hexafluoride lipid microspheres as an intravesical bolus injection through a 6 to 8 french urinary catheter. Continue filling bladder with NS until patient has the urge to micturate or at first sign of back pressure. Immediately following the first voiding, the bladder may be refilled with NS only for a second cycle of voiding and imaging.</p></div>
<div class="block sts drugH1Div" id="F26416887"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store intact and reconstituted vials at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Discard reconstituted suspension 3 hours after preparation. Discard unused suspension.</p>
<p style="text-indent:-2em;margin-left:2em;">SonoVue [Canadian product]: Store intact and reconstituted vials at 15°C to 25°C (59°F to 77°F). Discard reconstituted suspension 6 hours after preparation. Discard unused suspension.</p></div>
<div class="block usep drugH1Div" id="F53571178"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Ultrasonography:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Liver: </i>Characterization of focal liver lesions during ultrasound of the liver (FDA approved in pediatric patients [age not specified] and adults).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract:</i> Evaluate suspected or known vesicoureteral reflux during ultrasonography of the urinary tract (FDA approved in pediatric patients [age not specified]).</p>
<p style="text-indent:-2em;margin-left:2em;">Echocardiography: Opacification of the left ventricular chamber and improved delineation of the left ventricular endocardial border in patients with suboptimal echocardiograms (FDA approved in pediatric patients [age not specified] and adults).</p></div>
<div class="block cyt drugH1Div" id="F26189976"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F26189973"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F26416882"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53571179"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Cardiopulmonary reactions; signs and symptoms of anaphylactoid reactions (during and after administration).</p></div>
<div class="block pha drugH1Div" id="F26416889"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ultrasound contrast agent for cardiovascular imaging and hepatic and urinary tract ultrasonography.</p></div>
<div class="block phk drugH1Div" id="F26416891"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: Cardiovascular imaging 1.7 to 3.1 minutes (useful contrast effect)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: Sulfur hexafluoride (SF<sub>6</sub>): 341 L (0.03 mL/kg dose); 710 L (0.3 mL/kg dose)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Little or none</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: SF<sub>6</sub>: ~10 minutes (0.3 mL/kg dose; half-life could not be estimated at the 0.03 mL/kg dose)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: SF<sub>6</sub>: 1 to 2 minutes; up to 4 minutes in pulmonary impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: SF<sub>6</sub>: Lungs (88% unchanged)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F26531305"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Sonovue | Sulphur hexafluoride</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Sono vue</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lumason</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Sonovue</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Lumason.1">
<a name="Lumason.1"></a>Lumason (sulfur hexafluoride lipid-type A microspheres) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28377467">
<a name="28377467"></a>Muskula PR, Main ML. Safety with echocardiographic contrast agents. <i>Circ Cardiovascular Imaging.</i> 2017;10(4). pii: e005459. doi: 10.1161/CIRCIMAGING.116.005459<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfur-hexafluoride-lipid-microspheres-pediatric-drug-information/abstract-text/28377467/pubmed" id="28377467" target="_blank">28377467</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  SonoVue (sulfur hexafluoride) [product monograph]. Montreal, Quebec, Canada: Bracco Imaging Canada; December 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 126554 Version 32.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
